Dianthus Therapeutics公布近期业务进展,包括三期Captivate CIDP试验启动决定及2025财年第四季度和全年财务业绩

美股速递
Mar 09

Dianthus Therapeutics Inc. (以下简称Dianthus Therapeutics) 近日重点通报了其近期的多项业务里程碑。其中,最引人注目的是公司已正式决定推进其关键性三期临床试验——Captivate CIDP研究。此举标志着其在慢性炎症性脱髓鞘性多发性神经根神经病(CIDP)治疗领域的研发迈入决定性阶段。

与此同时,该公司还公布了2025财年第四季度及全年的财务报告,详细披露了期间的财务状况与运营表现。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10